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Hypothalamic neuropeptides orexin-A and orexin-B play critical roles in the regulation 
of sleep/wakefulness, as well as in a variety of physiological functions including 
emotion, reward and energy homeostasis. The effects of orexin peptides are mediated by 
two receptors, orexin 1 (OX1R) and orexin 2 (OX2R) receptors. These receptors show 
differential expression patterns depending on brain regions and neuron types, suggesting 
their differential roles. Here, we review the current understanding of the physiological 





The actions of orexins are mediated by two G-protein-coupled receptors, 
orexin 1 (OX1R) and orexin 2 (OX2R) receptors (Sakurai et al. 1998). OX1R has a 
one-order higher affinity for orexin-A than for orexin-B, while OX2R binds orexin-A 
and orexin-B with similar affinities. Both receptors are coupled to the Gq/11 subclass of 
G-proteins and have caused strong excitatory effects on neurons examined thus far 
(Mieda et al. 2013), except in one study that reported the direct inhibitory action of 
orexin receptors on surprachiasmatic nucleus (SCN) neurons at night (Belle et al. 2014). 
When overexpressed, OX2R has also been reported to couple to Gi/o in a neuronal cell 
line, suggesting that OX2R could exert inhibitory action in some neurons (Zhu et al. 
2003). 
In clear contrast to the restricted localization of orexin mRNA expression 
exclusively in neurons distributed within the lateral hypothalamus (LH) and perifornical 
area (PFA) (Date et al. 1999; de Lecea et al. 1998; Nambu et al. 1999; Peyron et al. 
1998; Sakurai et al. 1998), OX1R and OX2R mRNA show wide distributions within the 
brain with partly overlapping but distinct and complementary distributions (Marcus et al. 
2001; Mieda et al. 2011). This is consistent with the fact that orexin neurons project to 
almost all brain areas, with especially dense ones to monoaminergic and cholinergic 
nuclei of the brainstem and hypothalamus, which play important roles in the regulation 
of sleep/wakefulness states (Chemelli et al. 1999; Nambu et al. 1999; Peyron et al. 
1998). These nuclei express OX1R and OX2R in differential manners. Histaminergic 
neurons in the tubelomammilary nucleus (TMN) exclusively express OX2R, while 
noradrenergic neurons in the locus coeruleus (LC) exclusively express OX1R. In the 
dorsal raphe (DR) and median raphe (MnR), serotonergic neurons express OX1R and/or 
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OX2R. In the laterodorsal tegmental nucleus (LDT) and pedunculopontine tegmental 
nucleus (PPT), cholinergic neurons express OX1R but not OX2R mRNA (Marcus et al. 
2001; Mieda et al. 2011). Intriguingly, there are many GABAergic neurons expressing 
orexin receptors which are intermingled with these monoaminergic and cholinergic 
neurons. 
 
Disruption of the Orexin System Causes Narcolepsy 
Degenerative loss of orexin neurons in humans is associated with narcolepsy 
(type I narcolepsy: narcolepsy with cataplexy), a debilitating neurological disorder, 
providing a unique perspective on the mechanisms of sleep/wakefulness control 
(Sakurai and Mieda 2011; Zeitzer et al. 2006). A series of discoveries leading to this 
conclusion started with findings by two animal studies: (i) functionally null mutations in 
the OX2R gene were found to be responsible for familial canine narcolepsy (Lin et al. 
1999), and (ii) orexin knockout mice (orexin-/-) were shown to exhibit a phenotype 
strikingly similar to human narcolepsy (Chemelli et al. 1999). 
Human narcolepsy affects approximately 1 in 2,000 individuals in the United 
States (Mignot 1998; Sakurai and Mieda 2011; Zeitzer et al. 2006). The syndrome 
consists of excessive daytime sleepiness that often results in sleep attacks (sudden onset 
of non–rapid eye movement [NREM] sleep), cataplexy (sudden bilateral skeletal muscle 
weakening triggered by emotions, without consciousness impairment), hypnagogic 
hallucinations, and sleep paralysis. These symptoms can be divided into two 
independent pathological phenomena (Dauvilliers et al. 2007). The first is dysregulation 
of NREM sleep onset: the inability to maintain a consolidated awake period, 
characterized by abrupt transitions from wakefulness to NREM sleep. This phenomenon 
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manifests clinically as excessive daytime sleepiness or sleep attacks. The second 
pathological phenomenon is dysregulation of rapid eye movement (REM) sleep onset: 
the pathological intrusion of REM sleep or REM atonia into wakefulness or at sleep 
onset. It is during these periods that patients may experience cataplexy, hypnagogic 
hallucinations, and sleep paralysis. 
Similarly, orexin–/– mice display a phenotype strikingly similar to human 
narcolepsy, with markedly decreased duration of wakefulness episodes during the dark 
phase (i.e., inability to maintain a long wakeful period, or sleepiness), abrupt behavioral 
arrests with muscle atonia (i.e., potential cataplexy), which manifest as direct transitions 
from wakefulness to REM sleep in electroencephalogram/electromyogram (EEG/EMG) 
recordings, decreased REM sleep latency, and increased REM sleep time during the 
dark phase (Chemelli et al. 1999). 
 
Genetic dissection of sleep/wakefulness regulation by orexin receptors 
The fact that functionally null mutations in the OX2R gene were responsible for two 
independent lines of familial narcoleptic canines indicates OX2R-mediated pathway as 
a critical signaling in the regulation of sleep and wakefulness (Lin et al. 1999). Studies 
of orexin receptor-deficient mice (OX1R-/- and OX2R-/- mice) have provided a deeper 
insight into the differential roles of OX1R and OX2R (Fig. 1)(Sakurai 2007). First, 
OX1R-/-;OX2R-/- mice demonstrate a narcoleptic phenotype nearly similar to that in 
orexin-/- mice, confirming that orexinergic regulation of sleep/wakefulness is mediated 
by these two receptors. OX1R-/- mice show little abnormality in the states of sleep and 
wakefulness in the baseline condition (Hondo et al. 2010; Sakurai 2007). In contrast, 
OX2R-/- mice have clear narcoleptic symptoms, although their phenotype is milder as 
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compared to that found in orexin-/- mice (Sakurai 2007; Willie et al. 2003). During the 
dark phase, OX2R-/- mice did show abrupt cataplexy-like behavioral arrests, which 
correlated with the occurrence of direct transitions from wakefulness to REM sleep in 
EEG/EMG recordings (Fig. 1). However, the frequency of such arrests was far less as 
compared to orexin-/- mice (31-fold lower frequency in OX2R-/- mice than in orexin-/- 
mice). Importantly, close observation of the behavior of OX2R-/- mice during the dark 
phase using infrared videophotography uncovered a distinct variety of behavioral arrests 
with more gradual onsets (gradual arrests). Moreover, such gradual arrests turned out to 
also manifest in orexin-/- mice with a frequency similar to OX2R-/- mice, in addition to 
plenty of abrupt arrests. Abrupt and gradual arrests have been characterized as the 
presumptive mouse correlates of cataplexy and sleep attacks in human narcolepsy, 
respectively, according to their behavioral, pharmacological, and electrophysiological 
features (Willie et al. 2003). Consistent with this observation, wakefulness episodes of 
OX2R-/- mice are fragmented to an extent similar to those of orexin-/- mice, indicating 
that these two strains of mouse suffer from comparable sleepiness (Fig. 1). In contrast, 
OX2R-/- mice show normal REM sleep latency and amount of REM sleep, which are 
profoundly shortened and increased, respectively, in both orexin-/- mice and 
OX1R-/-;OX2R-/- mice (Willie et al. 2003). 
Collectively, mouse reverse genetic studies suggest that the normal regulation 
of wakefulness and NREM sleep transitions depends critically on OX2R activation, 
whereas the profound dysregulation of REM sleep control unique to narcolepsy emerges 
from loss of signaling through both OX1R- and OX2R-dependent pathways. 
This conclusion has been further confirmed by a complementary experiment, 
i.e., comparing the arousal effects of ICV orexin-A administration between wild-type, 
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OX1R-/-, and OX2R-/- mice (Fig. 2)(Mieda et al. 2011). The effects of orexin-A on 
wakefulness and NREM sleep were significantly attenuated in both OX1R-/- and OX2R-/- 
mice as compared to wild-type mice, with substantially larger attenuation in OX2R-/- 
than in OX1R-/- mice, suggesting the pivotal role of OX2R and the additional role of 
OX1R in the promotion of wakefulness. By contrast, the suppression of REM sleep via 
orexin-A administration was marginally and similarly attenuated in both OX1R-/- and 
OX2R-/- mice, suggesting a comparable contribution of the two receptors to REM sleep 
suppression (Mieda et al. 2011). The supplementary role of OX1R in the suppression of 
NREM sleep is consistent with the fact that OX2R-/- mice with a C57BL/6J, but not 
C57BL/6J-129/SvEv-mixed, genetic background show less fragmented wakefulness 
than orexin-/- mice and OX1R-/-;OX2R-/- mice (Hasegawa et al. 2014; Mochizuki et al. 
2011; Sakurai 2007; Willie et al. 2003), which suggests that OX1R is indispensable for 
the maintenance of wakefulness in the absence of OX2R. 
The conclusion drawn from mouse genetics apparently contradicts the fact 
that an inherited canine model of narcolepsy, which demonstrates a frequent occurrence 
of cataplexy as well as excessive sleepiness, is attributable solely to mutations of the 
OX2R gene (Lin et al. 1999). Species differences (e.g., the precise expression patterns 
of the two orexin receptors) and/or selection bias may explain such an inconsistency. It 
should be noted that, even in canines, the absence of orexin peptides may cause severe 
narcoleptic symptoms as compared to OX2R mutation. Early studies reported that 
narcoleptic Dobermans and Labradors with OX2R mutations were much less severely 
affected with cataplexy than poodles with sporadic narcolepsy, which were supposed to 
lack orexin peptides (Baker et al. 1982). 
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Sites of expression of orexin receptors relevant to the physiological control of 
sleep/wakefulness  
The application of exogenous orexins has been shown to excite many types of neurons. 
Monoaminergic and cholinergic nuclei of the hypothalamus and brainstem involved in 
the regulation of sleep and wakefulness especially receive dense projections of orexin 
neurons, express orexin receptors, and are activated by the application of orexin 
peptides in slice preparations (Bayer et al. 2001; Brown et al. 2001; Burlet et al. 2002; 
Eggermann et al. 2001; Eriksson et al. 2001; Horvath et al. 1999; Liu et al. 2002; van 
den Pol et al. 2002; Yamanaka et al. 2002; Mieda et al. 2013). Furthermore, the 
administration of orexin-A directly into the LC (Bourgin et al. 2000), TMN (Huang et al. 
2001), BF cholinergic area (Espana et al. 2001; Thakkar et al. 2001), and LDT (Xi et al. 
2001) has also been reported to increase wakefulness. However, neurons activated by 
the pharmacological application of exogenous orexin may not necessarily be essential to 
the endogenous mechanisms by which orexin neurons regulate sleep and wakefulness in 
a physiological condition. Thus, neurons directly downstream from orexin neurons in 
physiological conditions (i.e., the site and subtype of orexin receptors that mediate the 
wake-promoting and REM-gating effects by endogenous orexins) have remained 
incompletely understood. 
Histaminergic neurons in the TMN, which express OX2R exclusively, are 
good candidates for such downstream neurons contributing the arousal effect of orexin. 
Wake-promoting effect of ICV orexin-A administration is both markedly attenuated by 
the histamine H1 receptor (H1R) antagonist pyrilamine (Yamanaka et al. 2002) and is 
absent in H1R-/- mice (Huang et al. 2001). In addition, Mochizuki et al. produced 
OX2R-deficient mice by inserting a loxP-flanked transcription-disrupter (TD) gene 
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cassette into the OX2R gene, in which normal OX2R expression could be restored by 
Cre recombinase-mediated excision of TD cassette (Mochizuki et al. 2011). Using such 
an elegant genetic model, they showed that focal restoration of OX2R expression in the 
TMN and adjacent regions completely reversed the fragmentation of wakefulness 
episodes observed in their OX2R-deficient mice. 
However, this hypothesis remains controversial. Mice lacking both OX1R and 
H1R demonstrate no abnormality in sleep or wakefulness, which contradicts the idea 
that H1R-mediated histaminergic pathway is the principal downstream component of 
OX2R-mediated orexinergic signaling (Hondo et al. 2010). Moreover, a recent study 
showed that increased probability of sleep-to-wakefulness transitions by optogenetic 
activation of orexin neurons does not depend on histamine (Carter et al. 2009). 
Recently, we searched for monoaminergic and cholinergic nuclei of the 
brainstem and hypothalamus in which the focal restoration of orexin receptor expression 
by recombinant AAV vectors ameliorates narcoleptic phenotype of OX1R-/-;OX2R-/- 
mice (Fig. 3A)(Hasegawa et al. 2014). If the regional restoration of orexin receptors in a 
certain brain region suppresses narcoleptic symptoms in these mice, that particular 
region can at least be regarded as one of the important downstream targets of orexin 
neurons. The targeted restoration of orexin receptor expression in the DR and LC of 
these mice differentially inhibited cataplexy-like episodes and the fragmentation of 
wakefulness (i.e., sleepiness), respectively. The suppression of cataplexy-like episodes 
correlated with the number of serotonergic neurons restored with orexin receptor 
expression in the DR, while the consolidation of fragmented wakefulness correlated 
with the number of noradrenergic neurons restored in the LC. Furthermore, the 
pharmacogenetic activation of these neurons using DREADD (designer receptor 
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exclusively activated by designer drug) technology ameliorated narcolepsy in mice that 
lacked orexin neurons (Fig. 3B). These results suggest that DR serotonergic and LC 
noradrenergic neurons play differential roles in the regulation of sleep and wakefulness 
by orexin neurons. 
The suppression of cataplexy-like episodes by DR serotonergic neurons, but 
not by LC noradrenergic neurons, was an unexpected result (Hasegawa et al. 2014), 
because previous pharmacological and electrophysiological studies suggested that LC 
noradrenergic neurons are good candidates for downstream neurons to prevent cataplexy. 
For example, drugs that increase noradrenergic tone strongly suppress cataplexy in 
humans and canines, while blocking the noradrenergic signaling increases the frequency 
of cataplexy (Hirai and Nishino 2011; Nishino and Mignot 1997). In addition, LC 
neurons cease firing during cataplexy in canines (Wu et al. 1999). Nevertheless, our 
observations never deny the clinical importance of enhancing noradrenergic systems for 
preventing cataplexy, yet simply indicate that the sole regulation of LC noradrenergic 
neurons by endogenous orexins is not sufficient to suppress cataplexy in narcoleptic 
mice. Non-LC noradrenergic neurons may also play an important role in the suppression 
of cataplexy by the pharmacological augmentation of systemic noradrenergic tone, 
which may be independent of the orexinergic regulation. 
The contribution of orexin signaling in DR serotonergic neurons in the 
suppression of cataplexy fits with the observations that these neurons express both 
OX1R and OX2R (Mieda et al. 2011) and that the disruption of both OX1R- and 
OX2R-mediated pathways is required for the frequent occurrence of cataplexy, as 
described earlier (Sakurai 2007)(Fig. 4A). DR serotonergic neurons greatly reduce 
firing rates during cataplexy in canines (Wu et al. 2004). In addition, these neurons, as 
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well as LC noradrenergic neurons, have been implicated in the suppression of REM 
sleep by inhibiting REM-on cholinergic neurons in the PPT/LDT and/or by activating 
REM-off GABAergic neurons in the ventrolateral periaqueductal gray (vlPAG) and 
adjacent lateral pontine tegmentum (LPT), also known as dorsal deep mesencephalic 
reticular nuclei (dDpMe) (Pace-Schott and Hobson 2002; Luppi et al. 2011). Indeed, we 
observed dense projections of DR serotonergic neurons to these brain areas, as well as 
to the amygdala (Hasegawa et al. 2014), which suggests that DR serotonergic neurons 
may coordinately control multiple brain regions involved in the regulation of REM 
sleep and emotion. 
As described above, the fragmentation of wakefulness is less severe in 
OX2R-/- mice than in orexin-/- mice and OX1R-/-;OX2R-/- mice with C57BL/6J genetic 
background (Mochizuki et al. 2011; Sakurai 2007), suggesting that OX1R plays an 
important role in the maintenance of wakefulness in the absence of OX2R (Mieda et al. 
2011). Indeed, restoration of OX1R expression in the LC noradrenergic neurons of 
OX1R-/-;OX2R-/- mice stabilized wakefulness episodes to an extent comparable to those 
in OX2R-/- mice (Hasegawa et al. 2014). Considering the fact that LC noradrenergic 
neurons exclusively express OX1R in wild-type mice (Mieda et al. 2011), these neurons 
may be responsible for the contribution of OX1R to the maintenance of wakefulness, 
while another OX2R-mediated mechanism, most likely mediated by TMN histaminergic 
neurons, is further required for fully maintained wakefulness as in normal mice (Fig. 
4B). Recent optogenetic studies have provided supports for the importance of the 
orexinergic regulation of LC noradrenergic neurons in the consolidation of wakefulness. 
For instance, there is a causal relationship between the firing of LC noradrenergic 
neurons and transitions from sleep to wakefulness (Carter et al. 2010). Moreover, the 
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optogenetic inactivation of these neurons prevents the arousal effects of the optogenetic 
stimulation of orexin neurons (Carter et al. 2012). 
 
Pharmacological dissection of sleep/wakefulness regulation by orexin receptors  
A series of non-selective (dual) antagonists for orexin receptors (DORA), as well as 
subtype-selective antagonists (SORA), have been developed. On the one hand, these 
drugs are drawing people’s attention as novel medications for insomnia and other 
diseases (Scammell and Winrow 2011; Sakurai 2014). On the other hand, they are also 
useful for studying the roles of each subtype in the regulation of sleep/wakefulness. 
To a large extent, results obtained by pharmacological studies utilizing 
DORAs and SORAs are consistent with those derived from genetic studies described in 
the previous sections. Selective blockade of OX2R efficiently increases NREM sleep 
and shortens NREM sleep latency (Dugovic et al. 2009; Betschart et al. 2013; Dugovic 
et al. 2014; Etori et al. 2014; Gozzi et al. 2011). Blockade of both OX1R and OX2R 
does increases NREM sleep, but also causes disproportionally large increase in REM 
sleep (Bonaventure et al. 2015; Dugovic et al. 2009; Dugovic et al. 2014; Etori et al. 
2014; Hoyer et al. 2013). Except one study showing increases in REM and NREM sleep 
with SB-334867 (Morairty et al. 2012), selective blockade of OX1R alone does not 
cause any effects with statistical significance on baseline sleep/wakefulness 
(Bonaventure et al. 2015; Dugovic et al. 2009; Dugovic et al. 2014; Gozzi et al. 2011; 
Steiner et al. 2013). Thus, OX2R is the principal regulator of wakefulness/NREM sleep 
transition, while both OX1R- and OX2R-mediated pathways are critical for gating REM 
sleep.  
Administration of DORAs seldom induces cataplexy in normal animals, 
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although there is a report that less than half of rats treated with high doses of 
SB-649868 demonstrated direct transitions from wakefulness to REM sleep (Dugovic et 
al. 2014). Therefore, as compared to the induction of NREM and REM sleep, nearly 
complete and/or chronic absence of both OX1R- and OX2R-mediated pathways may be 
needed for cataplexy to occur. This notion is consistent with the observation that 
degeneration of more than 95% of orexin neurons is required for the occurrence of 
cataplexy in mice, whose frequency subsequently increases along with further 
degeneration (Tabuchi et al. 2014). 
 
Conclusions and future directions 
Genetic and pharmacological studies have dissected the differential roles of orexin 
receptors in sleep/wakefulness regulation. These two approaches have both merits and 
demerits. Knockout mice provide clear animal models with specific and complete 
removal of one of two subtypes. However, chronic compensatory changes should 
always be taken into account. In contrast, SORAs can acutely block one of two, 
eliminating any compensatory effects. On the other hand, specificity, potency, efficacy, 
occupancy, and stability of the administered drugs should be considered.  
Broad expression of orexin receptors throughout the brain complicates 
identifying neurons and orexin receptor subtypes directly regulated by endogenous 
orexins, mediating their wake-stabilizing effects. We and others have tackled this 
problem with a strategy of brain region/cell type-specific rescues of orexin receptors. In 
addition to such an approach, future studies utilizing brain region/cell type-specific 
genetic deletions of orexin receptors and pharmacological studies of focal 
administration of SORAs, as well as optogenetic and pharmacogenetic strategies, would 
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further uncover the differential roles of orexin receptors and neuronal pathways 





Fig. 1. Sleep state abnormalities in orexin receptor knockout mice. Representative 12-h 
dark-period (20:00–08:00) hypnograms for wild-type (WT), OX1R-/-, OX2R-/-, and 
OX1R-/-;OX2R-/- mice, all with a C57BL/6J background, are shown. The different levels 
above the baseline indicate states of sleep and wakefulness (e.g., REM, NREM, and 
wakefulness) of mice at the time. Episodes of direct transition from wakefulness to 
REM sleep are shown by arrows. Note the greater awake and NREM sleep episode 
fragmentation and reduced duration of wakefulness in the hypnograms of OX2R-/- and 
OX1R-/-;OX2R-/- mice compared with WT and OX1R-/- mice. Episodes of direct 
transition from wakefulness to REM sleep were not observed in OX1R-/- mice, and were 
hardly observed in OX2R-/- mice, though they were frequently observed in OX1R-/- and 
OX2R-/- mice. Modified from (Sakurai 2007). 
 
Fig. 2. Differential effects on sleep/wakefulness states following activation of OX1R 
and OX2R. Dose responses of the effect of ICV orexin-A in wild-type (WT), OX1R-/-, 
OX2R-/-, and OX1R-/-;OX2R-/- mice on time spent in wakefulness, NREM sleep, and 
REM sleep following administration. Modified from (Mieda et al. 2011). 
 
Fig. 3. Search for the downstream targets of orexin neurons to prevent narcolepsy. (A) 
Restoration of orexin receptor expression in the DR and LC inhibits cataplexy-like 
episodes and consolidates wakefulness, respectively, in narcoleptic OX1R-/-;OX2R-/- 
mice. Orexin receptor expression was restored in the nuclei indicated in 
OX1R-/-;OX2R-/- mice by recombinant AAV vectors. (B) Pharmacogenetic activation of 
DR serotonergic and LC noradrenergic neurons suppresses cataplexy-like episodes and 
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consolidates wakefulness, respectively, in narcoleptic mice lacking orexin neurons 
(orexin/ataxin-3 mice). Orexin/ataxin-3 mice with DR serotonergic neuron–selective  
or LC noradrenergic neuron–selective  expression of excitatory DREADD hM3Dq 
were injected with saline or CNO, the artificial ligand for DREADDs. Hourly plots of 
number of cataplexy-like episodes and mean duration of wakefulness episodes within 
12 hours after saline or CNO administration at ZT 12 (arrows) are shown. Modified 
from (Hasegawa et al. 2014). 
 
Fig. 4. Proposed model for OX1R- and OX2R-mediated pathways in suppressing 
narcoleptic symptoms. (A) Prevention of cataplexy-like episodes. (B) Consolidation of 
wakefulness episodes. Modified from (Hasegawa et al. 2014). 
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